INSTITUTE FOR SKIN ADVANCEMENT(4.6 mi away)Contact
+18 other location
A Phase 3, randomized (2:2:1), double-blind, 8-week vehicle control efficacy and safety study of ruxolitinib followed by a randomized, double-blind, 44-week long term safety (LTS) extension period. In the LTS period, participants initially randomized to vehicle will receive either ruxolitinib 0.75% or 1.5% cream. All participants will have follow-up assessments 30 (+7) days after the last application of study drug
For more information, please contact Incyte Corporation at 1.855.463.3463
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.